May 16, 2007
Cleveland Clinic Study Demonstrates TASER X26 Does Not Affect Short-Term Function of Implantable Pacemakers and Defibrillators
SCOTTSDALE, AZ - TASER International, Inc. (NASDAQ: TASR), a market leader in advanced electronic control devices announced today the publication of a study by Cleveland Clinic. According to the peer reviewed study published in Europace, by the European Society of Cardiology®, a standard electrical discharge from a TASER® X26 electronic control device (ECD) does not affect the integrity of implantable pacemakers and defibrillators and did not trigger an implantable cardioverter defibrillator (ICD) shock in devices programmed to the standard non-committed shock delivery mode.
As is well known, implantable cardiac devices are sometimes susceptible to malfunction as a result of electromagnetic interference (EMI). EMI can result in many undesirable consequences, including damage to internal circuitry, oversensing, undersensing, failure to pace, failure to capture, power on reset, triggering of elective replacement indicators or inappropriate defibrillation shocks.
This study evaluated the immediate effects of TASER X26 discharges on the function of various models of pacemakers and ICDs from the three major manufacturers. A small 50 lb (28 kg.) anesthetized adult pig served as an animal model. It concluded that the TASER X26 discharges do not affect the short-term functional integrity of implantable pacemakers and defibrillators even when the darts are placed in a manner to surround the implanted device. Also, the standard ECD application duration of five seconds should not trigger an ICD shock in devices programmed to the standard non-committed shock delivery mode.
"A standard five-second TASER X26 application does not affect the functional integrity of pacemakers and defibrillators," said Dr. Lakkireddy, who was the primary investigator for this study. Dr. Lakkireddy was an electrophysiology fellow at the Cleveland Clinic at the time of the study and is now a clinical assistant professor of medicine at the University of Kansas Hospital and a practicing cardiac electrophysiologist at the Bloch Heart Rhythm Center in Kansas City, KS.
This study was presented as an abstract at the Heart Rhythm Society (HRS) 2007 28th Annual Sessions in Denver, CO on May 12, 2007. The full manuscript was electronically published in Europace and is available at: http://europace.oxfordjournals.org/cgi/reprint/eum058?ijkey=v5zONNAwEzrMZP5&keytype=ref.
This study was funded by an educational grant from TASER International. The funding source had no input on the study design, organization, results and manuscript preparation. None of the contributing authors have any kind of financial or any other conflict of interest with the funding source.
About TASER International, Inc.
TASER International provides advanced electronic control devices for use in the law enforcement, military, private security and personal defense markets. TASER® devices use proprietary technology to incapacitate dangerous, combative or high-risk subjects who pose a risk to law enforcement officers, innocent citizens or themselves in a manner that is generally recognized as a safer alternative to other uses of force. TASER technology saves lives every day, and the use of TASER devices dramatically reduces injury rates for police officers and suspects. For more information on TASER life-saving technology, please call TASER International at (800) 978-2737 or visit our website at www.TASER.com.
Note to Investors
This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of the 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by those sections. The forward-looking information is based upon current information and expectations regarding TASER International. These estimates and statements speak only as of the date on which they are made, are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results could materially differ from what is expressed, implied, or forecasted in such forward-looking statements.
TASER International assumes no obligation to update the information contained in this press release. TASER International's forward looking statements in this press release and future results may be impacted by the completion of the restatement of the Company's financial results for the first quarter of 2005 and the second quarter of 2005, risks associated with rapid technological change, new product introductions, new technological developments and implementations, execution issues associated with new technology, ramping manufacturing production to meet demand, litigation results from Company filed lawsuits and other litigation including lawsuits resulting from alleged product related injuries, media publicity concerning allegations of deaths occurring after use of the TASER device and the negative impact this could have on sales, product quality, implementation of manufacturing automation, potential fluctuations in quarterly operating results, adjustments to these amounts which may be reflected in our 10Q filing, competition, financial and budgetary constraints of prospects and customers, international order delays, dependence upon sole and limited source suppliers, negative reports concerning TASER device uses, governmental inquiries and investigations, medical and safety studies, fluctuations in component pricing, government regulations, variation among law enforcement agencies with their TASER product experience, TASER device tests and reports, dependence upon key employees, and our ability to retain employees. TASER International's future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Qs and its Annual Report on Form 10-K.
The statements made herein are independent statements of TASER International. The inclusion of any third parties does not represent an endorsement of any TASER International products or services by any such third parties.